

HUMAN NAMkind™ IBD

Can your therapy restore the barrier?



Evaluate barrier function, inflammation and fibrosis in human disease tissue for ulcerative colitis and Crohn's disease.

Patient-derived

Human disease tissue

Disease-relevant biology

14-21 days

Repeat dosing

Follow the tissue response


Same-donor

Study controls

Benchmark treatment effects

Connect disease biology to response with tissue health measured alongside efficacy.

Human biology at the center of your study.



Schematic illustration; not to scale.

What does a meaningful response look like?

Compare effects on the barrier, inflammation and fibrogenesis alongside viability and metabolic activity.

Bring your UC or Crohn's program.

Ask our team about your next study.

DETAILS ON REVERSE



HUMAN NAMkind™ IBD

Measure efficacy. Resolve the tissue response.

Combine disease-relevant readouts with tissue health.

Standard endpoint panel

INCLUDED

ASSAY	WHAT IT MEASURES
TEER	Barrier integrity
ATP	Tissue viability
Alamar Blue	Metabolic activity
P1NP	Fibrogenesis
IL-6	Inflammatory signaling

Go deeper with custom assays

ADDITIONAL FEE

- | | |
|----------------------------------|--------------------------|
| • Immunohistochemistry | Desired antigens |
| • Picrosirius Red (PSR) staining | Collagen deposition |
| • Soluble fibrogenic biomarkers | ProC3, P3NP |
| • RNAseq | Transcriptomic profiling |

Build a study around your next decision.

01 / QUESTION

Barrier, inflammation, fibrosis

02 / STUDY DESIGN

Colon / ileum, dosing, controls

03 / READOUTS

Standard + custom assays

Let's design your efficacy study.

contact@vivosim.ai

vivosim.ai

SCAN TO
EMAIL US

